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ABSTRACT 
Background: Cytomegalovirus (CMV) disease has been associated with the development of chronic 
lung allograft dysfunction (CLAD) after lung transplantation. However, the relevance of 
asymptomatic CMV viremia occurring after the discontinuation of antiviral prophylaxis (late-onset 
CMV replication) on the development of CLAD is not fully understood. We aimed to assess the long-
term clinical impact of asymptomatic CMV replication in a cohort of lung transplant recipients 
receiving universal antiviral prophylaxis.  
Methods: We performed a single-center study including all patients who underwent lung 
transplantation between 2004 and 2014. Patients received valganciclovir prophylaxis for 3 to 6 months 
(according to CMV serostatus risk of the donor [D] and recipient [R]), followed by monitoring of 
CMV replication by PCR during the first year post transplant. CLAD was defined according to ISHLT 
definitions. Risk factors for the development of CLAD and for mortality were assessed by univariate 
and multivariate Cox models. A lineal regression model was used to evaluate the influence of CMV 
replication in the evolution of FEV1.  
Results: Overall, 69 patients were included. CMV serostatus was D-/R- in 13 (19%) patients, D-/R+ 
in 17 (25%) patients, D+/R+ in 27 (39%) patients and D+/R- in 12 (17%) patients. Overall, 34/69 
(49%) patients developed at least one episode of asymptomatic CMV replication and 8/69 (11.5%) 
patients developed CMV disease. Median duration of CMV replication in viremic patients was 57.5 
days. After a median follow-up of 3.69 years, 25/69 (36%) patients developed CLAD and 14/69 (20%) 
patients died. In the univariate cox analysis, bacterial pneumonia was associated with a higher 
incidence of CLAD (HR 2.58, p=0.06), but asymptomatic CMV replication (HR 1.36, p=0.45), CMV 
disease (HR 1.00, p=0.99), and duration of CMV replication (HR 1.00, p=0.76) were not. In the 
multivariate model, bacterial pneumonia remained associated with CLAD (HR 2.53, p=0.06). In the 
mixed model of linear regression, we did not observe a correlation between CMV replication and a 
significant decline of FEV1 (estimate -0.162, CI 95% [-0.498 to 0.170], p=0.35). CMV replication was 
not associated with a higher mortality (HR 0.75, p=0.62). 
Conclusion: In this cohort of lung transplant recipients receiving antiviral universal prophylaxis, 
asymptomatic CMV replication did not influence long-term allograft lung function and patient 
survival. These results suggest that the use of universal prophylaxis is protective against the indirect 
effects of CMV, irrespective of the development of late-onset CMV replication.  
Key words: viral infection, chronic lung allograft dysfunction, lung transplantation, outcomes 
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1. INTRODUCTION 
1.1 Lung transplantation 
The first lung transplantation ever was performed in 1963 and the patient survived only 18 
days. Much has changed over these last decades, as lung transplantation is today the preferred 
treatment for many end-stage lung diseases, such as chronic obstructive pulmonary disease 
(COPD), interstitial lung diseases and cystic fibrosis. Worldwide, the amount of lung 
transplantation procedures achieved has dramatically increased since 1990. In 2014, 56 lung 
transplantations were performed in Switzerland, which of 24 were done at the Lausanne 
University Hospital (CHUV) (1). Median waiting time for lung transplantation was 465 days, 
with a stable waiting list since 2010 (Figure 1). In 2014, 8 patients died waiting for a lung.  
 
 
1.2 Outcome after lung transplantation 
The survival after lung transplantation has been increasing worldwide since 1990. In the era 
between 1990 and 1997, the median survival post-transplantation was 4.3 years. It has now 
reached 6.3 years for the 2005-2012 era (2). The median survival for single and double-lung 
transplantation according to the data from the ISHLT registry is shown in figure 2. However, 
survival after transplant depends on many different factors. Better survival is correlated with 
younger and female recipients, as well as the underlying lung disease of the recipient. When 
considering adjusted survival (patients surviving at least one year), median survival was the 
longest for CF patients (11 years) followed by idiopathic pulmonary arterial hypertension 
(IPAH), sarcoidosis and COPD associated with α1-antitrypsin deficiency. Transplant 
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En 2014, la liste comptait 124 patients en attente d’un 
cœur, c’est-à-dire une augmentation de 6,9 pour cent par 
rapport à l’année précédente. Le nombre des transplan-
tations du cœur a légèrement augmenté (plus 9,1 pour 
cent) par rapport à 2013. Les transplantations se répar-
tissent comme suit sur les trois centres : 44,4 pour cent 
des transplantations ont été effectués à Zurich, puis vient 
Lausanne avec 30,6 pour cent et Berne avec 25 pour cent. 
Un tiers des 36 patients au total a été transplanté d’ur-
gence, à chaque fois quatre patients par centre.
Poumons
Après un recul du nombre de patients en attente d’un pou-
mon en 2013, les chiffres ont à nouveau atteint l’année 
dernière le niveau de 2012, ce qui correspond à une aug-
mentation de 9,9 pour cent. Sur les 122 patients en at-
tente d’un don susceptible de leur sauver la vie, 56 ont pu 
être transplantés. Il s’agit là de 11 transplantations sup-
plémentaires par rapport à 2013, soit une augmentation 
de 24,4 pour cent. 43 pour cent des transplantations ont 
été effectués à Lausanne et 57 pour cent à Z rich. Au to-
tal, 10 patients ont reçu en urgence une greffe du pou-
mon (17,9 pour cent).
Transplantations par organe
4.3
Nombre de transplantations cardiaques par centre/ 
transplantations en statut urgent
2010 2011 2012 2013 2014
Berne 10/4 10/3 10/3 12/3 9/4
CURT Lausanne 13/2 12/2 14/2 11/2 11/4
Zurich 12/2 14/3 11/3 10/2 16/4
Total 35/8 36/8 35/8 33/7 36/12
Nombre de transplantations pulmonaires par centre/ 
dont en statut urgent
2010 2011 2012 2013 2014
CURT Lausanne 23/7 24/3 19/1 17/4 24/3
Zurich 26/4 30/3 33/9 28/13 32/7
Total 49/11 54/6 52/10 45/17 56/10
32
Figure	  1:	  Lung	  transplantation	  in	  Switzerland	  
and	  waiting	  list,	  year	  2014	  (Swisstransplant	  
annual	  report	  2014)	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recipients receiving a double-lung transplantation have a better survival (7 years vs 4.5 years 
for single transplant) (2).  
 
	  
Figure	  2:	  Median	  survival	  for	  single	  and	  double	  lung	  transplant	  recipients	  (ISHLT	  registry) 
 
1.2.1 Causes of death 
The most common causes of death within the first 30 days post-transplantation are graft 
failure and technical or cardiovascular causes. Infections are a major cause of death at any 
time. After the first year, another main cause of death is chronic lung allograft dysfunction 
(CLAD), which includes processes like bronchiolitis obliterans syndrome (BOS) that will be 
discussed later. Main causes of death are listed in table 1.  
 
First 30 days - Graft failure 
- Infectious complications 
- Surgical complications 
- Cardiovascular causes 
First year  - Infectious complications 
After 1st year - Chronic lung allograft dysfunction 
- Infectious complications 
Table	  1:	  main	  causes	  of	  death	  following	  lung	  transplantation	  (ISHLT	  registry) 
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1.2.2 Risk factors for mortality 
Patients with BOS or acute rejection in the first-year post-transplant have a higher risk of 
mortality at 5 years (2). In a study involving 23’704 lung transplant recipients, the mortality 
risk model at 5 years demonstrated a negative impact from advanced recipient age and lower 
transplant center volume. The impact of age seems to be restricted to the recipient, as age 
appears not to be relevant when considering donor age. In fact, it was observed that allograft 
from older donors (>65 years old) did not affect the survival, although there seems to be a 
negative effect when given to a younger recipient (3). With the aging of the population, this 
question must be further studied to assess the impact of transplantation including older (>60 
years old) donors or recipients. Other risk factors that may influence patient survival are listed 
in table 2. 
  
5-year post-transplant - Underlying lung disease of recipient 
- Retransplantation 
- Earlier era of transplant 
- Increased severity of recipient illness at the time of 
transplantation (intensive care unit) 
- Donor history of diabetes 
- CMV mismatch (D+/R-) 
- Lower transplant center volume 
- Older recipient at age of transplant 
- Higher pretransplant supplemental oxygen required 
- Lower cardiac output 
Table	  2:	  Risk	  factors	  of	  death	  following	  lung	  transplantation	  (ISHLT	  registry)	  
 
1.2.3 Quality of life 
Lung transplantation has a positive impact on the quality of life (QoL) (4). There is an 
improvement in many dimensions of health - as defined by the Nottingham health profile - 
except for the aspects of pain and mental health. However there is a clear improvement in 
dimensions such as social life or physical mobility.  
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1.3 Immunosuppressive regimen 
1.3.1 Induction therapy 
At the time of transplantation, induction therapy is used to prevent the immune system of the 
recipient, especially T-cells, to attack the allograft. Induction agents are either monoclonal 
agents (i.e basiliximab, daclizumab) or polyclonal agents (anti-lymphocytes, anti-thymocytes). 
There is some conflict in the literature about the efficacy or superiority of one agent for 
induction therapy. There may be some benefit using monoclonal agents to prevent from onset 
of chronic rejection (5), but other studies do not confirm this hypothesis (6). Of note, 50% of 
centers do not generally use induction therapy, and this without a clear negative impact on 
allograft and patient survival.  
 
1.3.2 Maintenance therapy 
The aim of maintenance therapy is to keep a balance between over-immunosuppression that 
will lead to infection and under-immunosuppression that will cause allograft rejection. 
Different agents are used low-dose, to minimize the potential toxic adverse effects. Usual 
treatment combines three agents:  
1. Glucocorticoids, i.e prednisone: always used for immunosuppression. It inhibits both 
the adaptative and innate immune system and down-regulates the transcription of 
inflammatory genes (7) 
2. Calcineurin inhibitors: main agents are cyclosporine and tacrolimus. Both agents are 
inhibiting T-cell activity, but tacrolimus is now more widely used, especially among 
lung transplant recipients (8). Tacrolimus has less nephrotoxic adverse effects and 
may reduce the onset of BOS (9), but is more diabetogenic.  
3. Nucleotide blocking agents: usually azathioprine (AZA) or mycophenolate mofetil 
(MMF). While some studies have shown superiority of MMF over AZA treatment 
(10), this has not been confirmed in a randomized clinical trial (11).  
 
1.4 Allograft rejection and dysfunction 
1.4.1 Acute rejection 
They are three types of acute rejection: 
1. Cellular rejection: mediated by T-cells directed towards HLA antigens. It is the 
predominant type of acute rejection 
2. Humoral rejection: mediated by antibodies directed towards donor HLA 
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3. Hyperacute rejection: occurs within first 24 hours post-transplantation and is mediated 
by pre-formed antibodies from the recipient 
Acute rejection occurs in approximately one-third of lung transplant recipients (12). Acute 
rejection should be confirmed by a histological diagnosis, as an infectious process needs to be 
excluded. The difference between a rejection or an infectious process cannot be always done 
on clinical findings, as the presentation may be similar in some instances (13). Symptoms 
may occur mostly from A2 grade rejection and more.  
The actual nomenclature of allograft rejection has been established by the ISHLT in 2007 (14).  
A. Acute rejection: the diagnosis of acute rejection is made only on the presence of 
perivascular and interstitial mononuclear cell infiltrate. The grade can be between 0 
(no acute rejection) to grade 4 (severe) and reflects the most advanced pattern (and not 
the predominant one).  
B. Airway inflammation: lymphocytic bronchiolitis. This designation applies to small 
airways (bronchioles) and the grading is B0 (absent), B1 (low grade), B2 (high grade) 
or Bx (ungradable).  
C. Chronic airway rejection – obliterative bronchiolitis. This definition occurs when 
eosinophilic hyaline fibrosis in the sub-mucosa of membranous and respiratory 
bronchioles is seen, resulting in a partial or complete luminal occlusion. They may be 
associated with destruction of the smooth muscle and elastica of the airway. 
Mucostasis or foamy histiocytes are commonly associated with this phenomenon even 
in the absence of bronchiolar occlusion.  
D. Chronic vascular rejection – accelerated graft vascular sclerosis. This process is 
similar to coronary artery disease in the heart. It describes a fibrointimal thickening of 
arteries and veins.  
 
1.4.2 Chronic lung allograft dysfunction (CLAD) 
Surgical techniques and immunosuppressive regimens have greatly improved since 1963, 
however lung transplantation is still the solid organ transplantation (SOT) with least success, 
since 5 years survival is only 53% (15). The major factors that explain this disparity compared 
to other SOT is the highest incidence of chronic allograft rejection in lung transplant 
recipients, which is now defined as chronic lung allograft dysfunction (CLAD) (16).  
CLAD is not an etiological definition, but indicates that the lung is not achieving its full 
function. It is not irreversible per se, although it is usually a permanent condition. Depending 
on the spirometrical parameters, CLAD may present as a restrictive or an obstructive pattern.  
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• Bronchiolitis Obliterans Syndrome (BOS): decreased FEV1 (FEV1) <80% from 
baseline for > 3 weeks without any confounding condition and evidence of airflow 
obstruction (17). FEV1 baseline is defined as “the average of the two highest values 
for each measurement that were obtained at least three weeks apart post-transplant 
without the administration of a bronchodilatator” (17).  
• Restrictive Allograft Syndrome (RAS): FVC or TLC <80% baseline FVC or TLC for > 
3 weeks.  
We will discuss the pathogenesis and management of BOS in the next section. 
 
1.5 Bronchiolitis Obliterans Syndrome 
BOS is the clinical correlate of obliterative bronchiolitis (OB). OB is a histological diagnosis 
presenting as progressive obliteration of small airways. Because it was difficult to make this 
diagnosis via transbronchial lung biopsy, the actual consensus is to use BOS as the clinical 
marker of chronic allograft dysfunction. BOS is a major issue in lung transplantation as it 
represent the main cause of death adjusted for conditional survival of one year (18). The 
incidence reaches 50% within 5 years after transplantation (19) and the median survival after 
diagnosis is 3 years.  
 
1.5.1 Pathogenesis of BOS 
The first step of BOS is onset of lymphocytic infiltrates in the submucosa, with processes like 
lymphocytic bronchiolitis (LB) leading to epithelial injury. This injury will thus create the 
following sequence: necrosis  ulceration  inflammation that will end up by fibroblastic 
proliferation. Finally, the intraluminal polypoid granulation will eventually occlude totally or 
subtotally airways lumen (20). This is a complex process including immune and non-immune 
mechanisms. The molecular pathways are not fully understood yet, but we will shortly 
summarize the role of some cytokines in figure 3.  
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Figure	  3:	  cytokines	  involved	  in	  BOS	  pathogenesis	  (Adapted	  from	  Weigt	  and	  al,	  2010)	  
 
1.5.2 Risk factors of BOS 
Here are listed some risk factors for onset of BOS.  
• Alloimune mechanisms: BOS may be the clinical consequence of repeated acute 
rejections episodes (21). There is an increased risk of BOS when there are more HLA 
mismatches (22). Acute rejection may present with peri-airway infiltration of activated 
lymphocytes, which is described as lymphocytic bronchiolitis (LB). LB is recognized 
as the most significant risk factor for developing BOS (23).  
• Primary graft dysfunction (PGD): occurs typically within the first 24 hours after 
transplantation and is caused by events during the transplantation procedure, such as 
pulmonary ischemia or donor tissue preservation (20). There is evidence that not only 
it does affect the survival on a short term, but influences also the long-term survival 
and is hence considered a BOS risk factor.  
• Respiratory infections: community-acquired respiratory virus (CARV) have been 
identified as risk factor for BOS (24), and this risk was tripled when the lower 
respiratory tract was implicated. In smaller studies, Chlamydia pneumophilae and 
HHV-6 were also recognized as risk factors. The airway colonization by Pseudomonas 
aeruginosa and Aspergillus may be an independent risk factor for BOS as well (25) 
• Others: gastro-intestinal reflux, air pollution. 
CMV role will be discussed later in a separate section 
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1.5.3 Prevention and detection of BOS 
BOS is a clinical diagnosis mainly based on FEV1 evolution from baseline. However it needs 
some expertise by the transplant physician. There is an overall good agreement regarding the 
presence or absence of BOS diagnosis (26). There may be some variability when performing 
the spirometry, due to patient’s performance. One issue with BOS diagnosis is that it is 
retrospective by definition therefore the impact on the clinical management is limited. 
However there is some literature about how to predict or prevent onset of BOS. In a 
retrospective study including 121 patients, the measurement of CRP and neutrophilia in the 
broncho-alveolar lavage (BAL) at 90 days after transplantation was a predictive factor for 
determining the outcome of the allograft (27). Patients with BOS had a higher BAL CRP 
(cutoff >173 pg/ml) than the BOS-free group (BAL CRP baseline: 50 in stable group and 
540,4 in BOS group, p=0.002). CRP stimulates alveolar macrophages and alters surfactant 
function in the lungs which indicates a role during acute respiratory distress syndrome and 
could be used as a marker of lung injury (28). The use of azithromycine, a macrolide 
antibiotic with immunomodulatory effect, as prophylaxis (29) or treatment (30) is useful by 
inhibiting the neutrophilic airways inflammation pathway. When used as prophylaxis, it 
increases the BOS-free interval of 2.3 years and the pulmonary functions were significantly 
better (p=0.051). As a treatment, azithromycine given during 12 weeks increases the FEV1 
significantly (FEV1 difference between azithromycine and placebo group was 0.035 l and 
39% of patients in azithromycine group had >10% gain in FEV1 compared to 0% in the 
placebo group).  
 
1.6. Infections in a lung transplant recipients  
Infections are one of the most common causes of death after transplantation (2), usually 
presenting as pneumonia (31). The pathogens are mostly bacteria, with gram-negative rods 
such as Pseudomonas and Burkholderia being the most frequent causes of pneumonia in lung 
transplant recipients (31).  
 
1.7. Human cytomegalovirus 
Cytomegalovirus (CMV) is a double-stranded DNA virus in the family of Human herpes 
virus (HHV) and is also called HHV-5. CMV is transmitted by contact, blood transfusion or 
organ transplantation. In the immunocompetent host, the primary infection is usually 
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asymptomatic and CMV remains latent. However the virus may reactivate in case of stress or 
immunocompromise. 
Cytomegalovirus disease is the most important viral infection developing after SOT 
(32). CMV disease usually presents as a syndrome with fever, fatigue and body ache. 
Regardless of the type of transplant, CMV tissue-invasive disease usually involves the gastro-
intestinal tract, with complications such as hemorrhage or perforation. It can however also 
affect lungs, kidney, liver or any other organ (33). These effects are called the “direct effects” 
of CMV. Regarding lung transplantation, the main concern is about CMV pneumonitis, that 
causes alterations of the allograft.  
Moreover, CMV infection leads to many “indirect effects” - which cannot directly be 
related to a viral invasion of tissue - like an increased rate of bacterial and fungal infections or 
acute rejection (34). A relationship between kidney transplant, late-onset CMV infection and 
the concurrent post-transplant diabetes mellitus has been observed as well (35), suggesting a 
broad spectrum of indirect CMV effects. Direct and indirect effects are summarized in table 3. 
 
Direct Indirect 
- CMV syndrome 
- Tissue-invasive 
disease (mostly GI 
tract) 
- ↑ Bacterial, fungal infections 
- Acute and chronic rejection 
- Diabetes 
- More aggressive HCV infection after liver transplantation 
- Post transplant lymphoproliferative disorder 
- Death 
Table	  3:	  Direct	  and	  indirect	  effects	  of	  CMV	  	  
 
1.7.1. Risk factors for CMV infection 
The incidence of CMV infection depends on different factors. The most important one is the 
serostatus at transplantation. Naïve recipients receiving organs from seropositive donors 
(D+/R-) are considered at high-risk. Patients with either D-/R+ or D+/R+ seroconstellation are 
considered intermediate risk and finally D-/R- low risk (32). The state of immunosuppression 
also influences the risk of CMV disease (36). The risk also depends on the organ transplanted: 
lung, small intestine and pancreas have the highest risk of CMV, whereas liver and kidney 
have the lowest (36). Risk factors are summarized in table 4.  
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Risk factors for CMV disease 
- Serostatus 
- State of immunosuppression 
- Lung, small intestine or pancreas transplantation 
Table	  4:	  Risk	  factors	  for	  CMV	  disease	  
 
1.7.2. Immunomodulation and CMV 
To be able to maintain latency in the immunocompetent individual, CMV had to find ways to 
hide from the host immune system. For example, it interferes in the antigen presentation 
mechanism by producing HLA class I homologue that will block recognition by natural 
killers and other T cells (37) and also downregulates expression of antigen-presenting cells 
(APCs) (38). CMV also modulate the humoral immune mechanisms by producing its own FC 
receptor homolog (39). These receptors will bind circulating IgG and thus allow the infected 
cell to escape other immunoglobulin directed towards viral proteins. By altering cellular and 
humoral immune pathways, CMV inhibits the immune system in a non-specific manner, 
which would be likely to increase infection susceptibility in the host.  
 
1.7.3. CMV and allograft rejection 
There is a question whether CMV reactivation would increase the risk of allograft rejection or 
the allograft rejection would lead to CMV reactivation. The answer is that the mechanism is 
bidirectional, as summarized in Figure 8. Allograft rejection produces a pro-inflammatory 
cytokine (TNF) that will induce the reactivation of CMV (40). When CMV reactivates, it 
stimulates infected macrophages and AECs to produce molecules molecules that will increase 
the number of inflammatory cells in the lung. These molecules are endothelial adhesion 
molecules such as VCAM, ICAM, LFA-1 and VLA-4. It does also activates MHC class I 
antigen by molecular mimicry (41). Figure 4 shows this bidirectional interaction. There are 
some genetic factors affecting the susceptibility to CMV recurrence. Polymorphism in 
recipient’s genes coding for IFN-λ3 and IFN-λ4 influence the susceptibility to CMV 
replication in SOT recipients (42). This correlates with previous studies finding that these 
polymorphisms were associated with a reduced hepatitis C virus clearance. There is also an 
association between SNP polymorphisms of IFN-γ and CMV disease and high CMV viremia 
(43).  
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Figure	  4:	  Bidirectional	  interaction	  between	  CMV	  reactivation	  and	  allograft	  rejection	  (Adapted	  from	  Freeman	  
and	  al,	  2009) 
 
1.7.4. Management and prevention of CMV replication/disease in lung transplant recipients 
Strategies have been set to minimize the impact of CMV replication/disease on lung 
transplant recipients. The actual guidelines recommend a prophylactic approach over a 
preemptive one for high-risk (D+/R-) group with a 6 months therapy (44). Intermediate risk 
group (D-/R+, D+/R+) should be receiving 3 months of prophylaxis and there is no indication 
for prophylactic treatment regarding low-risk group (D-/R-). The use of universal prophylaxis 
with valganciclovir or ganciclovir has decreased overall the incidence of CMV infection and 
acute rejection in the current era (45).  
 
1.7.5. CMV infection and BOS 
CMV pneumonitis is a well-known risk factor for developing a BOS. With the development 
of antiviral prophylaxis for high-risk (D+/R-) group, the incidence has consequently 
diminished. However, CMV replication remains associated with graft rejection and graft loss 
(46) and D+/R- recipients have still a higher mortality than the other groups despite the 
prophylaxis, which means they should be followed more carefully and proactively (47). 
Nowadays, we have more technical tools that allow us to identify CMV DNAemia in the 
blood and it has been therefore noticed that there may be a subclinical CMV replication in the 
bloodstream. There is still a debate about the clinical relevance of these subclinical DNAemia. 
Some studies showed an correlation between CMV DNAemia episodes and onset of BOS 
(48), which was not confirmed by other studies (49).  
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1.8. Filling a literature gap 
The impact of CMV disease on survival and allograft function is nowadays well studied. 
CMV disease, especially CMV pneumonitis, occurring at an early or late stage is known as a 
risk for graft dysfunction and mortality (50). But the impact of asymptomatic CMV 
replication is not well defined yet and how to manage it in clinical practice. The aim of this 
study is to examine the potential clinical consequences of asymptomatic CMV replication in 
blood on allograft outcomes in a cohort of lung transplant recipients.  
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2. MATERIAL AND METHODS 
2.1 Study design and patient population 
We performed a single-center retrospective cohort study including all patients who underwent 
lung transplantation between 2004 and 2014 in the University Hospital of Lausanne (CHUV).  
Patients that were transplanted in Lausanne but had a follow-up in another transplant center 
(Basel, Bern of Geneva) were not included in the analysis.  
We reviewed patient’s records to collect demographic parameters, immunosuppressive 
regimens, FEV1 values, as well as infectious complications and episodes of acute rejection. 
The “Comission d’éthique de la recherche du canton de Vaud” approved the study protocol.  
 
2.2 Definitions in the study 
CMV infection was defined according to standard guidelines (44) by the evidence of CMV 
replication regardless of symptoms. CMV disease was the evidence of CMV infection with 
attribuable symptoms. CMV disease was further categorized as viral syndrome (fever, fatigue, 
myalgia) or end-organ disease (pneumonitis, colitis, gastro-enteritis or other). CLAD, BOS 
and RAS were classified according to ISHLT definitions. The term BOS is used when a 
persistent decline of FEV1 with no potential reversible cause found (30). Acute rejection was 
also defined following ISHLT definitions (14) which means the diagnosis of acute rejection is 
made only on the presence of perivascular and interstitial mononuclear cell infiltrate.  
 
2.3 Immunosuppressive regimen and antiviral prophylaxis 
The induction treatment was done with basiliximab. Maintenance therapy regimen used was 
tacrolimus, prednisone and mycophenolate mofetil (MMF). Patients at an intermediate risk 
for CMV serostatus (D+/R+ and D-/R+) received valganciclovir prophylaxis during 3 months 
and patients at high-risk (D+/R-) during 6 months. Patients with D-/R- serostatus received no 
anti-CMV prophylaxis, but anti-herpes prophylaxis with valaciclovir for 3 months. After 
discontinuation of prophylaxis, patients were monitored for CMV replication by PCR every 2 
weeks. The detection of CMV viral load in blood was done by PCR according to standard 
method (51).  
Lung function tests, including FEV1, FVC and 6 minutes walking test were measured 
at 3, 6, 12 months post-transplant and then each year and they were used to calculate the 
development of BOS and RAS.  
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2.4 Statistical analysis 
We aimed to assess the long-term clinical impact of asymptomatic CMV replication in a 
cohort of lung transplant recipients receiving universal antiviral prophylaxis.  
Descriptive statistics were used to describe the demographics and clinical characteristics of 
the population. Risk factors for the development of CLAD and for mortality were assessed by 
univariate and multivariate Cox models, including variables such as CMV replication, CMV 
diseasem CMV serostatus, other infectious complications (bacterial pneumonia, invasive 
fungal infection) and acute rejection. A lineal regression model was used to evaluate the 
influence of CMV replication in the evolution of FEV1.  
 
3. RESULTS 
3.1. Characteristics of the study population 
Overall, 69 patients were included in the study. The mean age was 52 years old and 61% of 
patients were female. Most patients received double-lung transplantation. The main 
indications for transplantation were COPD (40%) and cystic fibrosis (26%). The median 
duration of follow-up was 3.67 years. Overall, 17% of patients had a high-risk CMV 
serostatus (D+/R-). 81% of patients received antiviral prophylaxis with valganciclovir for a 
mean duration of 3.29 months and 14% received valaciclovir. Baseline characteristics and 
main outcomes are listed in tables 5 and 6.  
 
Demographic variables  All recipients 
Number of patients 69 
Time of follow-up in days, median 
(range) 
1341 (34-3806) 
Age, years mean (SD) 52.25 (14) 
Male sex (%) 27 (39%) 
Type of lung transplant (%) 
- single 
- double 
 
7 (11%) 
62 (89%) 
Underlying lung disease (%) 
- COPD 
- Cystic fibrosis 
- Other (IPF, alpha1AT 
deficiency, sarcoidosis) 
 
28 (41%) 
18 (26%) 
23 (33%) 
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Immunosuppressive regimen 
- Tacrolimus 
- MMF 
- Steroids 
 
68 (98%) 
64 (93%) 
69 (100%) 
CMV serostatus (%) 
- D-/R- 
- D-/R+ 
- D+/R+ 
- D+/R- 
 
13 (29%) 
17 (25%) 
27 (39%) 
12 (17%) 
Antiviral prophylaxis (%) 
- valganciclovir 
- valaciclovir 
 
56 (81%) 
10 (14%) 
Median duration of antiviral 
prophylaxis in days (range)  
91 (0-1464 
Table	  5:	  Baseline	  characteristics	  of	  the	  study	  population	  	  
Outcomes All recipients 
CMV asymptomatic replication n (%) 34 (49%) 
Duration of CMV replication, days, 
median (range) 
57.5 (1-506) 
CMV disease, n (%) 8 (11.5%) 
Pneumonia episodes (%) 41 (59%) 
Acute rejections (A1-A3) episodes (%) 36 (52%) 
CLAD (%) 25 (36%) 
CLAD free interval, median (range)  957 (237-2182) 
Death (%) 14 (20.3%) 
Table	  6:	  Main	  outcomes	  of	  patients	  included	  in	  the	  study 
 
3.2. CMV infection and disease 
Overall, 34/69 (49%) patients developed at least one episode of asymptomatic CMV 
replication and 8/69 (11.5%) developed CMV disease (3 patients presented with colitis, 2 
with pneumopathy, 1 with gastro-enteritis and 2 with other presentation). Median duration of 
CMV replication in viremic patients was 57.5 days.  
 
3.3. Risk factors for the development of chronic lung allograft dysfunction 
After a median follow-up of 3.67 years, 25/69 (36%) patients developed CLAD. Of the 25 
cases of CLAD, 22 were considered to be BOS and 3 were considered to be RAS.  
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Table 7 shows the univariate Cox analysis for risk factors associated with CLAD. 
Asymptomatic CMV replication (HR 1.36, p=0.45) and CMV disease (HR 1.00, p=0.76) were 
not associated with a higher risk for the development of CLAD. We observed a lower 
proportion of CLAD in the D-/R+ group (HR 0.289, p=0.123), but this was not statistical 
significant. The duration of valganciclovir prophylaxis did not have an influence on the 
development of CLAD. Bacterial pneumonia was associated with a higher incidence of 
CLAD (HR 2.58, p=0.06). Kaplan-Meier curves of CLAD-free survival according to CMV 
replication, CMV serostatus, acute rejection and bacterial pneumonia are shown in Figure 5.  
 
Variable Hazard 
ratio 
IC 95% P-value 
Sex (male) 0.775 0.345 1.741 0.538 
Age at Tx 0.998 0.970 1.027 0.897 
CMV replication 1.368 0.601 3.118 0.455 
Duration of CMV 
replication 
1.004 0.979 1.029 0.758 
CMV disease 1.001 0.297 3.374 0.998 
Duration of 
valganciclovir 
0.895 0.737 1.086 0.259 
CMV serostatus 
D-/R- (ref.) 1    
D-/R+ 0.289 0.060 1.402 0.123 
D+/R- 0.556 0.176 1.756 0.317 
D+/R+ 0.818 0.313 2.137 0.681 
Acute rejection 1.561 0.668 3.645 0.304 
Bacterial pneumonia 2.583 0.959 6.958 0.060 
Fungal infection 2.020 0.756 5.396 0.161 
Table	  7:	  Univariate	  Cox	  regression	  model	  of	  risk	  factor	  for	  the	  development	  of	  CLAD	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Figure	  5:	  Kaplan-­Meier	  curves	  on	  CLAD-­free	  survival	  according	  to	  CMV replication (above, left), CMV serostatus 
(above, right), acute rejection (below, left), and bacterial pneumonia (below, right)	  
 
In the multivariate model (table 8), bacterial pneumonia remained associated with CLAD (HR 
2.53, p=0.06) but CMV replication did not (HR 1.16, p=0.71).  
 
Variable Hazard 
ratio 
IC 95% P-value 
CMV replication 1.162 0.511 2.639 0.719 
Bacterial pneumonia 2.531 0.934 6.862 0.067 
Table	  8:	  Multivariate	  Cox	  regression	  model	  of	  risk	  factors	  for	  the	  development	  of	  CLAD 
 
In the mixed model of linear regression (Table 9), we did not observe a correlation between 
CMV replication and a significant decline of FEV1 (estimate -0,162, CI 95% [-0.498 to 
0.170], p=0.35).  
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Table	  9:	  Linear	  regression	  on	  the	  evolution	  of	  FEV1	  over	  time	  
 
3.4. Risk factors for mortality 
During the study period 14 out of the 69 patients died. In the univariate Cox model (Table 10), 
CMV replication was not associated with a higher mortality (HR 0.75, p=0.62). The presence 
of CLAD was not significantly associated with a higher mortality (HR 2.814, p=0.085). 
Kaplan-Meier curve of patient survival according to the presence of CLAD is shown in Figure 
6.  
	  
Figure	  6:	  Survival	  after	  lung	  transplantation	  according	  to	  the	  presence	  of	  CLAD	  	  
Univariate Cox model of the risk factors for mortality are shown in Table 10.  
Exposition	   HR	   HR	  CI	  95%	   p-­‐value	  
CLAD	   2.814	   0.866	   9.148	   0.085	  
CMV	  replication	   0.758	   0.250	   2.299	   0.625	  
Duration	  of	  CMV	  
replication	  
0.991	   0.953	   1.031	   0.667	  
CMV	  disease	   1.219	   0.272	   5.471	   0.796	  
Valganciclovir	   1.087	   0.964	   1.225	   0.174	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Sex	  (male)	   0.433	   0.135	   1.385	   0.158	  
Age	  at	  Tx	   1.010	   0.980	   1.060	   0.346	  
CMV	  serostatus	   	   	   	   	  
D-­‐/R-­‐	  (ref.)	   	   	   	   	  
D-­‐/R+	   1.302	   0.254	   6.663	   0.751	  
D+/R-­‐	   1.733	   0.413	   7.271	   0.452	  
D+/R+	   0.874	   0.191	   3.994	   0.863	  
Acute	  rejection	   0.958	   0.337	   2.728	   0.937	  
Bacterial	  pneumonia	   1.443	   0.458	   4.545	   0.531	  
Fungal	  infection	  	   0.436	   0.057	   3.336	   0.424	  
Table	  10:	  univariate	  Cox	  model	  of	  the	  risk	  factors	  for	  mortality 	  
4. DISCUSSION 
In our study, we aimed to assess the impact of late-onset CMV replication on allograft and 
patient outcomes in a single-center cohort of lung transplant recipients. We found that 
asymptomatic CMV replication occurring after the discontinuation of antiviral prophylaxis 
(i.e late-onset CMV replication) was not associated with a significant decrease in lung 
function and survival. The incidence of CLAD was similar in patients that developed CMV 
replication and there was no correlation between duration of CMV replication and the onset of 
CLAD. Moreover the decline of FEV1 was not affected by the development of CMV 
replication and there was no significant decrease of patient survival in patients with CMV 
replication. Finally, our results showed a decrease of patient survival in the CLAD group, 
which has already been widely accepted in the literature as the main cause of death in lung 
transplant recipients (17).  
These data suggest that asymptomatic CMV replication occurring after the 
discontinuation of antiviral prophylaxis does not have a major clinical impact in our 
population, as lung function and survival were not altered in patients with or without 
replication. However, the influence of CMV replication on allograft outcomes is still debated.  
It appears that the administration of antiviral drugs may have an impact on reducing the 
indirect effects of CMV, as most of the studies that found a relationship between CMV and 
allograft dysfunction were performed before the introduction of universal antiviral 
prophylaxis protocols. Another issue is whether detection of CMV in the allograft may be 
associated with different outcomes as respect to detection of CMV in blood. Some studies 
observed an association between CMV replication in the lung (CMV detected in BAL 
samples) and the occurrence of CLAD (48), which was not confirmed by another study (49). 
Because the CMV surveillance protocol was done more intensively in blood than in the BAL 
in our study, we decided to analyze only the presence of CMV in blood as the primary 
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endpoint. Our results showing a rather benign effect of CMV replication in lung transplant 
recipients may be useful for the management of these patients in the routine practice, as it 
might be not necessary to systematically monitor for CMV replication in asymptomatic 
patients.  
In addition to CMV disease, bacterial pneumonia and respiratory virus infections (52) 
have been associated with development of CLAD in the literature. In our results, bacterial 
pneumonia episodes were the only risk factor identified by our analysis that was associated 
with a higher incidence of CLAD, which suggests an association between infectious episodes 
and the development of allograft dysfunction. Although this has previously been reported, a 
clear mechanism of the association between bacterial infection and allograft dysfunction is 
not fully understood yet (53). Overall, these data suggest an important interaction between 
mechanisms of host defense against infection and rejection. The balance between on one hand 
too high immunosuppressive state and development of infection or, on the other hand not 
enough immunosuppressive state and development of rejection is a subtle adjustment, which 
need to be more explored to improve lung transplant recipients care.  
Our study has some limitations. First, this is a single-center study with the inherent 
biases of a retrospective study. Moreover, the modest sample size limited the strength of the 
analysis, especially regarding the multivariate analysis. However, we did not observe any 
trend towards a deleterious effect of CMV replication or CMV disease in terms of allograft or 
patient survival; so that we do not think that a larger sample size would have changed the 
results of our study. The main strength of our study is the relatively long-term follow-up, with 
a median follow-up duration of 3.67 years. Moreover, the immunosuppressive regimens, 
antiviral prophylaxis protocols and the management of infection were homogenous during all 
the study period, which have potentially diminished the bias associated with a different 
transplant care over time. CMV detection by PCR was hence performed in a single laboratory, 
which is relevant since CMV detection has a poor inter-center agreement (54).  
5. CONCLUSION 
Asymptomatic CMV replication in the blood did not affect the lung function or survival of 
lung transplant recipients receiving anti-CMV universal prophylaxis. These results suggest 
that universal prophylaxis given to patients according to their serostatus is protective 
regarding CMV as a risk factor for the onset of CLAD.  
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